Vilon vs Tirzepatide
Side-by-side comparison of key properties, dosing, and research.
Immune SupportAnti-Aging & Longevity
VilonGLP-1 / Weight Loss Agonists
Tirzepatide- Summary
- Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Half-Life
- Very short as a free dipeptide; effects mediated via gene regulation
- ~5 days
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 1–2 mg SC daily or 5–10 mg oral daily
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- Once daily
- Once weekly, subcutaneous
- Key Benefits
- Immune system modulation and restoration
- Lifespan extension (30–40% in animal studies)
- T-cell and NK-cell activation
- Epigenetic anti-aging activity
- Reduces oxidative stress markers
- Antioxidant gene upregulation
- May prevent age-related immune senescence
- Anti-tumor immune surveillance
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Side Effects
- Excellent safety profile, decades of Russian clinical use
- Rare: mild injection site reaction
- Very rare: mild allergic reaction
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Stacks With
- —
- —